David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
Commentary|Videos|March 19, 2026
Looking Towards the Future of Clinical Trials in Gynecologic Oncology
Author(s)John Moroney, MD, Katherine Kurnit, MD
Fact checked by: Kyle Doherty
John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss which future advances being examined in clinical trials in gynecologic oncology are catching their eyes.
Advertisement
John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss notable ongoing clinical trials in gynecologic oncology at the University of Chicago and beyond. They underscore that many of the most interesting approaches being examined are immunotherapy-based and also highlight trials using cellular therapies.
Advertisement
Related to this article
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer
3
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
4
UCSF Breast Cancer Specialists Share Expertise on Challenging Breast Cancer Type
5